DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma

Journal:

Nature Communications

Published:

2026-03-07

DOI:

10.1038/s41467-026-70120-z

Affiliations:

21

Authors:

24

Go to article

Institutions	Authors	Share
Pancreas Centre BC, Canada	2.500000	0.10
BC Cancer Research Centre (BCCRC), Canada	2.500000	0.10
Predicine, Inc., United States of America (USA)	2.000000	0.08
Queen's University, Canada	2.000000	0.08
Sir Mortimer B. Davis Jewish General Hospital (SMBD JGH), Canada	1.000000	0.04
The Ottawa Hospital (TOH), Canada	1.000000	0.04
London Health Sciences Centre (LHSC), Canada	1.000000	0.04
Centre Hospitalier de l’Université Laval (CHUL) Research Centre, UL, Canada	1.000000	0.04
University of Sherbrooke (USherbrooke), Canada	1.000000	0.04
Hospital of the University of Montreal (CHUM), Canada	1.000000	0.04
Moncton Hospital, Canada	1.000000	0.04
Hôpital de la Cité-de-la-Santé, Canada	1.000000	0.04
Sunnybrook Health Sciences Centre, U of T, Canada	1.000000	0.04
Arthur J.E. Child Comprehensive Cancer Centre (Arthur Child), AHS, Canada	1.000000	0.04
Queen Elizabeth II Health Sciences Centre, Canada	1.000000	0.04
Juravinski Cancer Centre, HHS, Canada	1.000000	0.04
CancerCare Manitoba (CCMB), Canada	1.000000	0.04
The University of British Columbia (UBC), Canada	0.500000	0.02
Vancouver General Hospital (VGH), Canada	0.500000	0.02
Princess Margaret Cancer Centre, U of T, Canada	0.500000	0.02
Ontario Institute for Cancer Research (OICR), Canada	0.500000	0.02

Interested in Oncology and Carcinogenesis?